The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
 
Meredith Becker Buxton
Employment - Berry Consultants
Consulting or Advisory Role - Amgen (Inst); Janssen (Inst); Lilly (Inst); Notable Labs (Inst)
Research Funding - Bayer (Inst)
 
Brian Michael Alexander
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Roche
Research Funding - Celgene (Inst); Lilly (Inst); Puma Biotechnology (Inst)
 
Donald A. Berry
Employment - Berry Consultants
Leadership - Berry Consultants
Stock and Other Ownership Interests - Berry Consultants
Consulting or Advisory Role - Berry Consultants
Research Funding - Daiichi Sankyo
Travel, Accommodations, Expenses - Berry Consultants
 
Webster K. Cavenee
Honoraria - Merck
 
Howard Colman
Consulting or Advisory Role - Abbvie; Bayer; Best Doctors, Inc; Deciphera; FORMA Therapeutics; Innocrin Pharma; Karyopharm Therapeutics; Newlink Genetics; Orbus Therapeutics; Private Health; Tactical Therapeutics
Research Funding - Abbvie (Inst); Array BioPharma (Inst); BeiGene (Inst); DNAtrix (Inst); FORMA Therapeutics (Inst); Global Coalition for Adaptive Research (Inst); Kadmon (Inst); Merck (Inst); Newlink Genetics (Inst); Orbus Therapeutics (Inst); Plexxikon (Inst)
 
John Frederick De Groot
Employment - ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; AstraZeneca; Blue Earth Diagnostics; Boston Biomedical; CarThera; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GenomiCare; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Kairos Ventures; KIYATEC; Merck; Mundipharma Research; Novogen; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support
Travel, Accommodations, Expenses - Blue Earth Diagnostics
 
Benjamin M. Ellingson
Consulting or Advisory Role - Agios; Bristol-Myers Squibb; Imaging Endpoints; Medicenna; MedQIA; Nativis; Northwest Biotherapeutics; Novogen; Omniox; Roche/Genentech; Siemens; Tocagen
Research Funding - Agios; Roche/Genentech; Siemens
Travel, Accommodations, Expenses - Siemens
 
Gary B. Gordon
Employment - Ayala Pharmaceuticals
Leadership - Ayala Pharmaceuticals; Global Coalition for Adaptive Research
Stock and Other Ownership Interests - Abbott; Abbvie; Chiasma; crispr therapeutics; Editas Medicine; Intellia Therapeutics; Medtronic; Molecular Templates; Pfizer
Consulting or Advisory Role - Intellia Therapeutics; Molecular Templates
Travel, Accommodations, Expenses - PhotonPharma
 
Mustafa Khasraw
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Lilly; Roche
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Andrew B. Lassman
Honoraria - Abbott Molecular; WebMD
Consulting or Advisory Role - Abbvie; Agios; Bayer; BioClinica; FORMA Therapeutics; Karyopharm Therapeutics; Northwest Biotherapeutics; Orbus Therapeutics; QED Therapeutics; SapVax
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agios (Inst); Amgen (Inst); Bayer (Inst); BeiGene (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Keryx (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); VBI Vaccines (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Oncoceutics
 
Wenbin Li
No Relationships to Disclose
 
Michael Lim
Honoraria - Accuray; Agenus; Bristol-Myers Squibb; Merck; Oncorus; Stryker; tocagen
Consulting or Advisory Role - Accuray; Baxter; Bristol-Myers Squibb; Merck; Stryker; VBI Vaccines
Research Funding - Accuray (Inst); Agenus (Inst); Arbor Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); CellDex (Inst); ImmunoCellular Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Methods Patent for Combining Immunotherapy with Radiation (Inst)
Travel, Accommodations, Expenses - Accuray; Baxter; Bristol-Myers Squibb; Merck; Stryker
 
Ingo K. Mellinghoff
Honoraria - Roche
Consulting or Advisory Role - Agios; Black Diamond Therapeutics; Debiopharm Group; Puma Biotechnology; Voyager Therapeutics
Research Funding - Amgen; General Electric; Lilly
Travel, Accommodations, Expenses - Agios; AstraZeneca; Puma Biotechnology; Roche; Voyager Therapeutics
 
James R. Perry
No Relationships to Disclose
 
Erik P. Sulman
Honoraria - BrainLAB; Merck Sharp & Dohme; Novocure; PER; Zai Lab
Consulting or Advisory Role - Abbvie; Blue Earth Diagnostics; Merck Sharp & Dohme; Novocure
Research Funding - Abbvie (Inst); Novocure (Inst)
Travel, Accommodations, Expenses - BrainLAB; Merck Sharp & Dohme; Novocure; PER; Zai Lab
 
Kirk Tanner
Employment - Vertex
Stock and Other Ownership Interests - Vertex
Honoraria - Vertex
Other Relationship - Oncoheros Biosciences
 
Michael Weller
Honoraria - Abbvie; Merck Serono; MSD
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Karyopharm Therapeutics; Merck Serono; Orbus Therapeutics; Tocagen
Research Funding - Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); OGD2 Pharma (Inst); Piqur (Inst); Roche (Inst); Tragara (Inst)
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; Deciphera; deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
W. K. Alfred Yung
Stock and Other Ownership Interests - DNATrix; Quadriga
Honoraria - DNAtrix
Consulting or Advisory Role - DNAtrix; Quadriga
Patents, Royalties, Other Intellectual Property - DNATrix
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; cortice; Deciphera; DelMar Pharmaceuticals; Genocea Biosciences; GW Pharmaceuticals; Human Longevity, Inc; Insys Therapeutics; Karyopharm Therapeutics; KIYATEC; Lilly; Merck; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pascal Biosciences; Pfizer; Puma Biotechnology; QED Therapeutics; Roche/Genentech; Sunovion; Tocagen; VBI Vaccines; VBL Therapeutics; wellcome trust
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Global Coalition for Adaptive Research